BridgeBio Pharma, Inc. reported significant financial developments in its latest quarterly filing, revealing a total revenue of $194.5 million for the three months ended March 31, 2026, a substantial increase from $116.6 million in the same period of 2025. This growth was primarily driven by a notable rise in net product revenue, which surged to $180.6 million from $36.7 million, attributed to the commercialization of its product Attruby. However, the company experienced a decline in license and services revenue, which fell to $4.4 million from $79.7 million, largely due to the recognition of a $75 million milestone payment in the previous year following the approval of Beyonttra in the EU.
Operating expenses also increased, totaling $300.5 million for the first quarter of 2026, compared to $221.0 million in the prior year. This rise was fueled by higher research and development costs, which reached $126.6 million, up from $111.4 million, reflecting ongoing investments in late-stage development programs. Selling, general, and administrative expenses also rose significantly to $163.9 million from $106.4 million, driven by increased external costs and personnel-related expenses associated with the commercialization of Attruby and preparations for other product candidates.
BridgeBio's net loss for the quarter was $166.6 million, slightly improved from a net loss of $169.6 million in the same quarter of 2025. The company reported a loss attributable to common stockholders of $164.0 million, translating to a net loss per share of $0.84, compared to $0.88 in the previous year. The company’s cash, cash equivalents, and marketable securities stood at $940.2 million as of March 31, 2026, a significant increase from $587.5 million at the end of 2025, bolstered by proceeds from the issuance of convertible senior notes.
Strategically, BridgeBio has made notable advancements, including the submission of a New Drug Application for BBP-418 for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) in March 2026. The company also initiated a stock repurchase program, allowing for the purchase of up to $500 million of its common stock, reflecting confidence in its long-term value. Additionally, BridgeBio has entered into various licensing agreements, including a significant deal with Bayer for acoramidis, which is expected to generate ongoing royalty revenue.
Looking ahead, BridgeBio anticipates continued operating losses as it invests in the commercialization of Attruby and the development of its pipeline products. The company remains focused on achieving profitability through its strategic initiatives and product launches, while also navigating the complexities of the biopharmaceutical market.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering transformative medicines for genetic diseases. Its core products include Attruby/Beyonttra, an oral therapy for transthyretin amyloid cardiomyopathy, and late-stage clinical candidates targeting achondroplasia, autosomal dominant hypocalcemia, and limb girdle muscular dystrophy. BridgeBio leverages genetic insights and innovative drug platforms to address high unmet medical needs, serving patients through regulatory approvals and strategic partnerships.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.